Targeting tuberculosis: A glimpse of promising drug targets

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 187-201

  Arora, N ^a   Banerjee, A K ^b  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Current therapy; Multi drug resistance; Mycobacterium tuberculosis; Novel drug targets; Tuberculosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; AMINOSALICYLIC ACID; BACTERIAL ENZYME; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISOCITRATE LYASE; ISONIAZID; KANAMYCIN; MENAQUINONE; PROTEASOME; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRAZINAMIDE; RIFAMPICIN; SHIKIMIC ACID; STREPTOMYCIN; TERPENOID; THIOL;

AMINO ACID SYNTHESIS; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BIOSYNTHESIS; DNA DAMAGE; DNA REPAIR; DRUG STRUCTURE; DRUG TARGETING; FATTY ACID SYNTHESIS; GENETIC TRANSCRIPTION; INFECTION CONTROL; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; REVIEW; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; SURVIVAL; TUBERCULOSIS;

EID: 84857861272     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511209030187     Document Type: Review

References (238)

1. Koch, R. Die Aetiologie der Tuberculose [The aetiology of Tuberculosis]. Berliner Klinische Wochenschrift, 1882.
2. Lange, C.; Yew, W.W.; Migliori G.B.; Raviglione, M. The European Respiratory Journal targets tuberculosis. European Respiratory Journal, 2010, 36, (4), 714-715.
3. Gagneux, S.; DeRiemer, K.; Van, T.; Kato-Maeda M.; Jong, B.C.D.; Narayanan, S.; Nicol, M.; Niemann, S.; Kremer, K.; Gutierrez, M. C.; Hilty, M.; Hopewell, P.C.; Small, P.M. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A., 2006, 21, 103(8), 2869-2873.
4. Murray, J.F. Tuberculosis and HIV Infection: A Global Perspective. Respiration, 1998, 65,335-342.
5. WHO Report, 2008. Global tuberculosis control - surveillance, planning, financing.
6. Russell, S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg., 2004, 71(2 Suppl), 147-55.
7. Bhowmik, D.; Chiranjib, R., Margret Chandira, B. Jayakar, K.P., Sampath Kumar. Recent trends of drug used treatment of tuberculosis. Journal of Chemical and Pharmaceutical Research, 2009, 1 (1), 113-133.
8. [Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. BMJ, 1948, ii, 7692.
9. Pyle, M.M. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet o Clin., 1947, 22, 465-72.
10. Youmans, G.P.; Williston, E.H.; Feldman, W.H.; Hinshaw, H. Increase in resistance of tubercle bacilli to streptomycin; a preliminary report. Proc Staff Meet o Clin., 1946, 21, 126-127.
11. Duncan, K.; Sacchettini, J.C. In, Hatfull GF, Jacobs WRJ Ed, Approaches to tuberculosis drug development. Molecular genetics of mycobacteria. Washington DC, ASM Press. 2000, 297-307.
12. Pablos-Mendez, A. Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000. Int. J. Tuberc. Lung Dis., 2000, 4(6), 489-90.
13. [World Health Organization. Global tuberculosis control: a short update to the 2009 report.
14. Espinal, M.A. The global situation of MDR-TB. Tuberculosis (Edinb). 2003; 83(1-3), 44-51.
15. Sharma, S.K.; Guleria, R.; Jain, D.; Chawla, T.C.; Saha, P.; Mohan, A.; et al. Effect of additional oral ofloxacin administration in the treatment of multidrug resistance tuberculosis. Indian J Chest Dis Allied Sci, 1996, 38,73-9.
16. Anderson, R.M. The pandemic of antibiotic resistance. Nature Med., 1999, 5,147-9.
17. Seaworth, B.J. Multidrug-resistant tuberculosis. Infect Dis Clin North Am., 2002, 16, 73-105.
18. Fisher, M. Diagnosis of MDR-TB: a developing world problem on a developed world budget. Expert Rev Mol Diagn, 2002, 2, 151-9.
19. Dye, C.; Williams, B.G.; Espinal, M.A.; Raviglione, M.C. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science, 2002, 295, 2042-6.
20. Chirac, P., Torreele, E. Global framework on essential health R&D. Lancet., 2006, 367,1560-1561.
21. World Health Organization. 2003. The World Health Organization Global Tuberculosis Program. http,//www.who.int/gtb/
22. Blumberg, H.M.; Burman, W.J.; Chaisson, R.E.; Daley, C.L.; Etkind, S.C.; Friedman, L.N.; Fujiwara, P.; Grzemska, M.; Hopewell, P.C.; Iseman, M.D.; Jasmer, R.M.; Koppaka, V.; Menzies, R.I.; O'Brien, R.J.; Reves, R.R.; Reichman, L.B.; Simone, P.M.; Starke, J.R.; Vernon, A.A. Am. J. Respir. Crit Care Med., 2003, 167, 603-662.
23. Barry, P.J.; O'Connor, T.M. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem., 2007, 14(18), 2000-2008.
24. Johnson, R.; Jordaan, A.M.; Pretorius, L.; Engelke, E.; van der Spuy, G.; Kewley, C.; Bosman, M.; van Helden, P.D.; Warren, R.; Victor, T.C. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis., 2006, 10(1), 68-73.
25. [Blanc, D.C.; Nunn, P. Incentives and Disincentives for New Anti- Tuberculosis Drug development: Situational Analysis. Geneva: World Health Organization, 2000. WHO/TDR/PRD/TB/00.1.
26. Cheng, A.F.; Yew, W.W.; Chan, E.W.; Chin, M.L.; Hui, M.M.; Chan, R.C. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother, 2004, 48, 596-601.
27. Brennan, P.J.; Nikaido, H. The Envelope of Mycobacteria. Ann. Rev. of Biochem., 1995, 64, 29-63.
28. Draper, P. The outer parts of the mycobacterial envelope as permeability barriers. Front. Biosci., 1998, 3, D1253-D1261.
29. Brennan, P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis, 2003, 83, 91-97.
30. Tam, P.H.; Lowary, T.L. Recent advances in mycobacterial cell wall glycan biosynthesis. Curr. Opin. Chem. Biol., 2009, 13(5-6), 618-25.
31. Chatterjee, D. The mycobacterial cell wall: structure, biosynthesis drug action. Curr.Opin.in Chem. Biol., 1997, 1, 579-568.
32. Brennan, P.J.; Crick, D.C. cell-wall core of Mycobacterium tuberculosis in the context of drug discovery. Curr. top.in med. chem., 2007,7, 475-88.
33. Crick, D.C.; Mahapatra, S.; Brennan, P.J. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology, 2001,11 (9), 107R-118R.
34. Baulard, A.R.; Besra, G.S.; Brennan, P.J. The cell-wall core of Mycobacterium: structure, biogenesis and genetics. In Ratledge, C. and Dale, J. (eds.), Mycobacteria, molecular biology and virulence. Blackwell Science Ltd, London, 1999, 240-259.
35. Rafidinarivo, E.; Lanéelle, M.A.; Montrozier, H.; Valero-Guillén, P.; Astola, J.; Luquin, M.; Promé, J.C.; Daffé, M. Trafficking pathways of mycolic acids: structures, origin, mechanism of formation, and storage form of mycobacteric acids. J. of Lipid Res., 2009, 50,477-490.
36. Sharma, K.; Chopra, P.; Singh, Y. Recent advances towards identification of new drug targets for Mycobacterium tuberculosis. Exp. Opin. on Ther. Tar., 2004, 8, 2, 79-93.
37. Glickman, M.S.; Jacobs, W.R. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell, 2001, 104, 477-485.
38. Indrigo, J.; Hunter, R.L.; Actor, J.K. Cord factor trehalose mediates trafficking events during mycobacterial 6, 69-dimycolate (TDM) infection of murine macrophages. Microbiology, 2003, 149, 2049-2059.
39. Devergne, O.; Emilie, D.; Peuchmaur, M.; Crevon, M.C.; DiAgay, M.F.; Galanaud, P. Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1-beta and interferongamma genes. Hum. Pathol., 1992, 23, 317-323.
40. Briken, V.; Porcelli, S.A.; Besra, G.S.; Kremer, L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol, 2004, 53,391-403.
41. Chatterjee, D.; Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. J Biol Chem, 1992, 267, 6228-6233.
42. Barry, C.E. III. New horizons in the treatment of tuberculosis. Biochem Pharmacol., 1997, 54, 1165-1172.
43. Besra, G.S.; Brennan, P.J. The mycobacterial cell envelope: a target for novel drugs against tuberculosis. J Pharm Pharmacol., 1997, 49(Suppl. 1), 25-30.
44. Tomioka, H.; Tatano, Y., Yasumoto, K.; Shimizu, T. Recent advances in antituberculous drug development and novel drug targets. Expert Review of Respiratory Medicine, 2008, 2, 4, 455-471.
45. Deng, L.; Mikusova, K.; Robuck, K.G.; Scherman, M.; Brennan, P.J.; McNeil, M. Recognition of multiple effects of ethambutol on the metabolism of the mycobacterial cell envelope. Antimicrob Agents Chemother., 1995,39, 694-701.
46. Takayama, K., Kilburn, J.O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother., 1989, 33, 1493-1499.
47. [Winder F G. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In, Ratledge C, Standford J, editors. The biology of the mycobacteria. Vol. 1. London, United Kingdom, Academic Press, 1982. 354-442.
48. [Ma, Y.; Stern, R.J.; Scherman, M.S.; Vissa, V.D.; Yan, W.; Jones, V.C.; Zhang, F.; Franzblau, S.G., Lewis, W.H.; McNeil, M.R. Drug targeting Mycobacterium tuberculosis cell wall synthesis, genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother., 2001, 45(5), 1407-16.
49. Slayden, R.A.; Lee, R.E.; Armour, J.W.; Cooper, A.M.; Orme, I.M. et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother., 1996. 40, 2813-19.
50. Kremer, L., Douglas, J.D., Baulard, A.R.; Morehouse, C.; Guy, M.R. et al. Thiolactomycin and related analogues as novel antimycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem., 2000, 275, 16857-64.
51. Parrish, N.M., Kuhajda, F.P.; Heine, H.S.; Bishai, W.R.; Dick, J.D. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. J. Antimicrob. Chemother., 1999, 43, 219-26.
52. Parrish, N.M.; Houston, T.; Jones, P.B.; Townsend, C.; Dick, J.D. In vitro Activity of a Novel Antimycobacterial Compound, NOctanesulfonylacetamide, and Its Effects on Lipid and Mycolic Acid Synthesis. Antimicrobial Agents and Chemotherapy, 2001, 45, 4, 1143-1150.
53. Bloch, K. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv Enzymol Relat Areas Mol Biol., 1977, 45, 1-84.
54. Veyron-Churlet, R.; Zanella-Cléon, I.; Cohen-Gonsaud, M.; Molle, V.; Kremer, L. Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. J. Biol. Chem., 2010, 285(17),12714-12725.
55. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris D.; et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-44.
56. [Kinsella, R.J.; Fitzpatrick, D.A.; Creevey, C.J.; McInerney, J.O. Fatty acid biosynthesis in Mycobacterium tuberculosis, Lateral gene transfer, adaptive evolution, and gene duplication. Proceedings of National Academy of Science, 2003, 2, 100 (18), 10320-10325.
57. Roujeinikova, A.; Levy, C.W.; Rowsell, S.; Sedelnikova, S.; Baker, P.J.; Minshull, C.A.; Mistry, A.; Colls, J.G.; Camble, R.; Stuitje, A.R.; Slabas, A.R.; Rafferty, J.B.; Pauptit, R.A.; Viner, R.; Rice, D.W. Crystallographic analysis of triclosan bound to enoyl reductase. J. Mol. Biol., 1999, 294(2), 527-535.
58. Heath, R.J.; Rubin, J.R.; Holland, D.R.; Zhang, E.; Snow, M.E.; Rock, C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem., 1999, 274(16), 11110-11114.
59. Hayashi, T.; Yamamoto, O.; Sasaki, H.; Kawaguchi, A.; Okazaki, H. Mechanism of action of the antibiotic thiolactomycin inhibition of fatty acid synthesis of Escherichia coli. Biochem. Biophys. Res. Commun., 1983, 115, 1108-1113.
60. Kuo, M.R.; Morbidoni, H.R.; Alland, D.; Sneddon, S.F.; Gourlie, B.B.; Staveski, M.M.; Leonard, M.; Gregory, J.S.; Janjigian, A.D. et al. Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase. The Journal of Biological Chemistry, 2003, 278(23), 20851-20859.
61. Mdluli, K.; Spigelman, M. Novel targets for tuberculosis drug discovery. Current Opinion in Pharmacology, 2006, 6(5), 459-467.
62. Brown, A.K.; Bhatt, A.; Singh, A.; Saparia, E.; Evans, A.F.; Besra, G.S. Identification of the dehydratase component of the mycobacterial mycolic acid-synthesizing fatty acid synthase-II complex. Microbiology. 2007, 153, 4166-4173.
63. Kremer, L.; Nampoothiri, K.M.; Lesjean, S.; Dover, L.G.; Graham, S.; Betts, J.; Brennan, P.J.; Minnikin, D.E., Locht, C.; Besra, G.S. Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA:AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II. J. Biol.Chem. 2001, 276(30), 27967-27974.
64. Smith, S.; Witkowski, A.; Joshi, A.K. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003, 42, 289-317.
65. Lou, Z.; Zhang, X. Protein targets for structure-based anti- Mycobacterium tuberculosis drug discovery. Protein & Cell, 2010, 1, 5, 435-442.
66. [Portevin, D.; De Sousa-D'Auria, C.; Houssin, C.; Grimaldi, C.; Chami, M.; Daffé, M.; Guilhot, C. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci U S A., 2004, 6, 101(1), 314-319.
67. Portevin, D.; de Sousa-D'Auria C, Montrozier, H.; Houssin, C.; Stella, A.; Lanéelle, M.A.; Bardou, F.; Guilhot, C.; Daffé, M. The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth, identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J. Biol Chem., 2005, 280(10), 8862-74.
68. Bouvier, F.; Rahier, A.; Camara, B. Biogenesis, molecular regulation, and function of plant isoprenoids. Prog Lipid Res., 2005, 44, 357-429.
69. Sacchettini, J.C., Poulter, C.D. Creating isoprenoid diversity. Science, 1997, 277, 1788-1789.
70. Buchanan, B.; Gruissem, W., Jones, R., Croteau, R., Kutchan, T.; Lewis, N. (2000) in Biochemistry and Molecular Biology of Plants, Natural products (secondary metabolites) eds Buchanan B, Gruissem W, Jones R (American Society of Plant Biologists, Rockville, MD), 1250-1268.
71. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343, 425-430.
72. Connolly, J.D.; Hill, R.A. In, Dictionary of terpenoids. New York, Chapman and Hall. 2002, 2156.
73. Chappell, J. Biochemistry and molecular biology of the isoprenoid biosynthetic pathway in plants. Ann Rev Plant Physiol Plant Mol Biol, 1995, 46, 521-47.
74. McGarvey, D.J.; Croteau, R. Terpenoid metabolism. Plant Cell, 1995, 7, 1015-26.
75. Hind, G.; Olson, J.M. Electron transport pathways in photosynthesis. Ann Rev of Plant Physiol 1968, 19, 249-82.
76. W. Growth retardants: Effects on gibberellin biosynthesis. and other metabolic pathways. Ann Rev of Plant Physiol and Plant Mol Biol., 2000, 51, 501-31.
77. Fenton, J.W.; Jeske, W.P., Catalfamo, J.L., Brezniak, D.V., Moon, D.G., Shen, G.X. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochem (Moscow) 2002, 67, 85-91.
78. Fenton, J.W.; Jeske, W.P., Catalfamo, J.L., Brezniak, D.V., Moon, D.G., Shen, G.X. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Translated from Biokhimiya 2002, 67, 99-106.
79. Bramley, P.M. Isoprenoid metabolism. In: Dey PM, Harborne JB Eds, Plant Biochemistry. London, Academic Press 1997, 417-37.
80. Singh, N.; Chevé G.; Avery, M.A.; McCurdy, C.R. Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery, Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme. Current Pharmaceutical Design, 2007, 13, 1161-1177 1161
81. Banthorpe, D.V.; Charlwood, B.V.; Francis, M.J. The biosynthesis of monoterpenes. Chem Rev., 1972, 72, 115-55.
82. Beytia, E.D.; Porter, J.W. Biochemistry of polyisoprenoid biosynthesis. Annu Rev Biochem., 1976, 45, 113-42.
83. Amdur, B.H.; Rilling, H.; Bloch, K. The enzymatic conversion of mevalonic acid to squalene. J Am Chem Soc., 1957, 79, 2646-7.
84. Eisenreich, W.; Bacher, A.; Arigoni, D.; Rohdich, F. Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell. Mol. Life Sci., 2004, 61, 1401-1426.
85. Sangari, F.J.; Pérez-Gil, J.; Carretero-Paulet, L.; García-Lobo, J.M.; Rodríguez-Concepción, M. A new family of enzymes catalyzing the first committed step of the methylerythritol 4- phosphate (MEP) pathway for isoprenoid biosynthesis in bacteria. PNAS, 2010, 107(32), 14081-6.
86. Brown, A.C.; Eberl, M.; Crick, D.C.; Jomaa, H.; Parish, T. The Nonmevalonate Pathway of Isoprenoid Biosynthesis in Mycobacterium tuberculosis Is Essential and Transcriptionally Regulated by Dxs, Journal of Bacteriology, 2010, 192(9), 2424-2433
87. Eoh, H.; Brennan, P.J.; Crick, D.C. The Mycobacterium tuberculosis MEP (2C-methyl-D-erythritol 4-phosphate) pathway as a new drug target. Tuberculosis, 2009, 89(1), 1-11.
88. [Rohdich, F.; Hecht, S.; Katrin, G.; Adam, P.; Krieger, C.; Amslinger, S.; Arigoni, D.; Bacher, A.; Eisenreich, W. Studies on the nonmevalonate terpene biosynthetic pathway, Metabolic role of IspH (LytB) protein. Proc Natl Acad Sci U S A., 2002 5, 99(3), 1158-1163.
89. Kuzuyama, T.; Takagi, M; Kaneda, K.; Tohru; Seto, H. Formation of 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritolfrom 2-Cmethyl- D-erythritol 4-phosphate by 2-C-methyl-Derythritol 4- phosphate cytidylyltransferase, a new enzyme in the nonmevalonate pathway. Tetrahedron Lett., 2000, 41:703-706.
90. Lichtenthaler, H.K.; Zeidler, J.; Schwender, J.; Muller, C. The nonmevalonate isoprenoid biosynthesis of plants as a test system for new herbicides and drugs against pathogenic bacteria and the malaria parasite. Z. Naturforsch., 2000, 55, 305-313.
91. Kuzuyama, T.; Shimizu, T.; Takahashi, S.; Seto, H. Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. Tetrahedron Lett., 1998,39, 7913-7916.
92. Arcus, V.L.; Lott, J.S.; Johnston, J.M.; Baker, E.N. The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov Today, 2006, 11(1-2), 28-34.
93. Janowski, R.; Kefala, G.; Weiss, M.S. The structure of dihydrodipicolinate reductase (DapB) from Mycobacterium tuberculosis in three crystal forms. Acta Crystallogr D Biol Crystallogr., 2010, 61-72.
94. Cox, R.J.; Sutherland, A.; Vederas, J.C. Bacterial diaminopimelate metabolism as a target for antibiotic design. Bioorg Med Chem., 2000, 8, 843-871.
95. Hutton, C.A.; Perugini, M.A.; Gerrard, J.A. Inhibition of lysine biosynthesis, an evolving antibiotic strategy. Mol BioSyst., 2007, 3, 458-465.
96. Hutton, C.A.; Southwood, T.J.; Turner, J.J. Inhibitors of lysine biosynthesis as antibacterial agents. Mini Rev Med Chem., 2003, 3, 115-127.
97. [Cherney, L.T.; Cherney, M.M.; Garen, C.R.; James, M.N. The structure of the arginine repressor from Mycobacterium tuberculosis bound with its DNA operator and Co-repressor, Larginine. J Mol Biol., 2009, 24,388(1), 85-97.
98. Bentley, R. The shikimate pathway. A metabolic tree with many branches. Crit Rev Biochem Mol Biol., 1990, 25, 307-384.
99. Herrmann, K.M. (1983). The common aromatic biosynthetic pathway. In Amino Acids, Biosynthesis and Genetic Regulation, K.M. Herrmann and R.L. Somerville, eds (Reading, MA Addison- Wesley),. 301-322.
100. Herrmann, K.M. The shikimate pathway as an entry to aromatic secondary metabolism. Plant Physiol, 1995, 107, 7-12.
101. Ducati, R.G. Mycobacterial Shikimate Pathway Enzymes as Targets for Drug Design. Current Drug Targets, 2007, 8, 423-435.
102. Parish, T.; Stoker, N.G. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology, 2002, 148 3069-3077.
103. Haslam, E. (1993) Shikimic Acid: Metabolism and Metabolites, J. Wiley and Sons, Chichester.
104. Garbe, T., Jones, C., Charles, I., Dougan, G.; Young, D. Cloning and characterization of the aroA gene from Mycobacterium tuberculosis. J Bacteriol, 1990, 172, 6774-6782.
105. Garbe, T., Servos, S., Hawkins, A., Dimitriadis, G., Young, D., Dougan, G.; Charles, I. The Mycobacterium tuberculosis shikimate pathway genes - evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases. Mol Gen Genet., 1991, 228, 385-392
106. Roberts, C.W.; Roberts, F.; Lyons, R.E.; Kirisits, M.J.; Mui, E.J., Finnerty, J. et al. The Shikimate Pathway and Its Branches in Apicomplexan Parasites. The Journal of Infectious Diseases, 2002, 185(Suppl 1), S25-36.
107. Gourley, D. G.; Shrive, A. K.; Polikarpov, I.; Krell, T.; Coggins, J. R.; Hawkins, A. R.; Isaacs, N. W.; Sawyer, L. The two types of 3- dehydroquinase have distinct structures but catalyze the same overall reaction. Nat Struct Biol, 1999, 6: 521-525.
108. Gu, Y.; Reshetnikova, L.; Li, Y.; Yan, H.; Singh, S. V.; Ji, X. Crystallization and preliminary X-ray diffraction analysis of shikimate kinase from Mycobacterium tuberculosis in complex with MgADP. Acta Crystallogr. D. Biol. Crystallogr., 2001, 57, 1870-1871.
109. Roberts, F.; Roberts, C.W.; Johnson, J.J.; Kyle, D.E.; Krell, T.; Coggins, J.R.; Coombs, G.H.; Milhous, W.K.; Tzipori, S.; Ferguson, D.J.; Chakrabarti D.; McLeod, R Evidence for the shikimate pathway in apicomplexan parasites. Nature, 1998, 393, 801-805.
110. McConkey, G.A. Targeting the Shikimate Pathway in the Malaria Parasite Plasmodium falciparum antimicrobial Agents and Chemotherapy, 1999, 43,1175-177.
111. Dias, M.V.; Borges, J.C.; Ely, F.; Pereira, J.H.; Canduri, F.; Ramos, C.H.; Frazzon, J. et al. Structure of chorismate synthase from Mycobacterium tuberculosis. J Struct Biol., 2006, 154:130-143.
112. Reichau, S.; Jiao, W.; Walker, S.R.; Hutton, R.D.; Baker, E.N.; Parker, E.J. Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: Combining mechanism- and modeling-based design. J Biol Chem, 2011, 286,16197-207
113. Koul, A.; Vranckx, L.; Dendouga, N. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result ofdisturbed ATP homeostasis. J Biol Chem., 2008, 283, 25273-25280.
114. Andries, K.; Verhasselt, P.; Guillemont, Jerome.; Hinrich, W.H.; Göhlmann Neefs J.; Winkler, H. et al., A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707), 223-227.
115. Weinstein, E.A.; Yano, T.; Li, L.S.; Avarbock, D.; Avarbock, A.; Helm, D.; McColm, A.A.; Duncan, K.; Lonsdale, J.T.; Rubin, H. Inhibitors of type II NADH, menaquinone oxidoreductase represent a class of antitubercular drugs. P Natl Acad Sci USA, 2005, 102, 4548-4553.
116. Bald, D.; Koul, A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 2010, 308(1), 1-7.
117. Sassetti, C.M.; Boyd, D.H.; Rubin, E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol., 2003, 48, 77-84.
118. Miesel, L.; Weisbrod, T.R.; Marcinkeviciene, J.A.; Bittman, R.; Jacobs, W.R.NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacterial., 1998, 180, 2459-2467.
119. Schnappinger, D.; Ehrt, S.; Voskuil, M.I. et al. Transcriptional adaptation ofMycobacterium tuberculosis within macrophages, insights into the phagosomal environment. J Exp Med., 2003, 198, 693-704.
120. Shi, L.B.; Sohaskey, C.D.; Kana, B.D.; Dawes, S.; North, R.J.; Mizrahi, V.; Gennaro, M.L. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci USA, 2005, 102, 15629-15634.
121. Boshoff, H.I., Barry, C.E.R. Tuberculosis-metabolism and respiration in the absence of growth. Nat Rev Microbiol, 2005, 3, 70-80.
122. Yano, T.; Li, L.S.; Weinstein, E.; Teh, J.S.; Rubin, H. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADHmenaquinone oxidoreductase (NDH-2). J Biol Chem., 2006, 281, 11456-11463.
123. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol., 2007, 3, 323-324.
124. Sareen, D.; Newton, G.L.; Fahey, R.C.; Nancy, A. Buchmeier. Mycothiol Is Essential for Growth of Mycobacterium tuberculosis Erdman Journal of Bacteriology, 2003, 185(22), 6736-6740.
125. Buchmeier, N.A.; Newton, G.L.; Koledin, T.; Fahey, R.C. Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics. Mol Microbiol., 2003, 47(6), 1723-32.
126. Buchmeier, N.; Fahey, R.C. The mshA gene encoding the glycosyltransferase of mycothiol biosynthesis is essential in Mycobacterium tuberculosis Erdman. FEMS Microbiol Lett., 2006, 264, 74-79.
127. Miller, C.C.; Rawat, M.; Johnson, T.; Av-Gay, Y. Innate Protection of Mycobacterium smegmatis against the Antimicrobial Activity of Nitric Oxide Is Provided by Mycothiol. Antimicrobial Agents and Chemotherapy, 2007, 51, 9, 3364-3366.
128. Newton, G. L.; Ta, P., Bzymek, K. P., Fahey, R. C. (Biochemistry of the Initial Steps of Mycothiol Biosynthesis. J. Biol. Chem., 2006, 281, 33910-33920.
129. Rawat, M.; Newton, G.L.; Ko, M.; Martinez, G.J.; Fahey, R.C.; Av-Gay, Y. Mycothiol-Deficient Mycobacterium smegmatis Mutants Are Hypersensitive to Alkylating Agents, Free Radicals, and Antibiotics. Antimicrobial Agents and Chemotherapy, 2002, 46(11), 3348-3355.
130. [Rawat, M.; Johnson, C.; Cadiz, V.; Av-Gay, Y. Comparative analysis of mutants in the mycothiol biosynthesis pathway in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun., 2007, 9, 363(1), 71-76.
131. Maynes, J.T.; Garen, C.; Cherney, M.M.; Newton, G.; Arad, D.; Av-Gay, Y.; Fahey, R.C.; James, M.N. The crystal structure of 1- D-myo-inosityl 2-acetamido-2-deoxy-alpha-D-glucopyranoside deacetylase (MshB) from Mycobacterium tuberculosis reveals a zinc hydrolase with a lactate dehydrogenase fold. J Biol Chem., 2003, 278, 47166-47170.
132. McCarthy, A.A.; Peterson, N.A.; Knijff, R.; Baker, E.N. Crystal structure of MshB from Mycobacterium tuberculosis, a deacetylase involved in mycothiol biosynthesis. J Mol Biol., 2004, 335, 1131-1141.
133. Vetting, M.W.; Roderick, S.L.; Yu, M.; Blanchard, J.S. Crystal structure of mycothiol synthase (Rv0819) from Mycobacterium tuberculosis shows structural homology to the GNAT family of Nacetyltransferases. Protein Sci., 2003, 12, 1954-1959.
134. Vetting, M.W.; Yu, M.; Rendle, P.M.; Blanchard, J.S. The substrate-induced conformational change of Mycobacterium tuberculosis mycothiol synthase. J Biol Chem., 2006, 281, 2795-2802.
135. Wheeler, P.D.; Blanchard, J.S. (2005) Metabolism and biochemical pathways. In Tuberculosis and the Tubercle Bacillus. Cole, S., Eisenach, K.D., McMurray, D.N., and Jacobs, W.R. (eds). Washington, DC, American Society for Microbiology Press, pp. 309-339.
136. Gennis, R.B.; Stewart, V. (1996) Respiration. In Escherichia coli and Salmonella. Neidhardt, F.C. (ed.). Washington DC, American Society for Microbiology Press, 217-261.
137. Mathew, R.; Kruthiventi, A.K.; Prasad, J.V.; Kumar, S. P.; Srinu, G.; Chatterji, D. Inhibition of Mycobacterial Growth by Plumbagin Derivatives. Chem Biol Drug Des., 2010, 76, 34-42.
138. Sherman, M.M.; Petersen, L.A.; Poulter, C.D. Isolation and characterization of isoprene mutants of Escherichia coli. J Bacteriol., 1989, 171, 3619-3628.
139. Kurosu, M.; Begari, E. Vitamin K2 in Electron Transport System,: Are Enzymes Involved in Vitamin K2 Biosynthesis Promising Drug Targets? Molecules, 2010, 15, 1531-1553.
140. Dhiman, R.K.; Mahapatra, S.; Slayden, R.A.; Boyne, M.E.; Lenaerts A.; Hinshaw, J.C.; Angala, S.K.; Chatterjee, D.; Biswas, K.; Narayanasamy, P.; Kurosu, M.; Crick, D.C. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Molecular Microbiology, 2009, 72(1), 85-97.
141. Suvarna, K.; Stevenson, D.; Meganathan, R.; Hudspeth, M. E. S. Menaquinone (Vitamin K2) Biosynthesis, Localization and Characterization of the menA Gene from Escherichia coli. Journal of Bacteriology, 1998, 180, 102, 782-2787.
142. [Kurosu, M.; Narayanasamy, P.; Biswas, K.; Dhiman, R.; Crick, D.C. Discovery of 1,4-Didydroxy-2-naphthoate Prenyltransferase Inhibitors, New Drug Leads for Multidrug-Resistant Gram-Positive Pathogens. J Med Chem., 2007, 23, 50(17), 3973-3975.
143. M. DNA topoisomerases. Annu. Rev. Biochem., 1981, 50, 879-910.
144. Maxwell, A. DNA gyrase as a drug target. Trends Microbiol., 1997, 5, 102.
145. Gundersen, L.L.; Nissen-Meyer, J.; Spilsberg, B. Synthesis and antimycobacterial activity of 6-arylpurines, the requirements for the N-9 substituent in active antimycobacterial purines. J. Med. Chem., 2002, 45, 1383.
146. Gellert, M.; Mizuuchi, K.; O'Dea, M.H.; Nash, H.A. DNA gyrase, an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A., 1976, 73, 3872-5.
147. Reece, R. J.; Maxwell, A. DNA gyrase, structure and Function. CRC. CRC Critical reviews in Biochemistry, 1991. 26, 335-75.
148. Levine, C.; Hiasa, H.; Marians, K. J. DNA gyrase and topoisomerase IV, biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta, 1998, 1400, 29-43.
149. de Souza, Marcus V.N. Promising Drugs against Tuberculosis. Recent Patents on Anti-Infective Drug Discovery, 2006, 1, 33-44, 33.
150. Drlica, K.; Zhao, X. DNA gyrase, Topoisomerase IV, and the 4- quinolones. Microbiol Mol Biol Rev., 1997, 61, 377-92.
151. Mitscher, L.A. Topoisomerase Inhibitors, Quinolone and Pyridone Antibacterial Agents Chem Rev., 2005, 105, 559-92.
152. Gellart, M.; O'Dea, M.H.; Itoh, T.; Tomizava, J. Novobiocin and coumeromycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A, 1976, 73, 4474-8.
153. Körner, H.; Sofia, H.J.; Zumft, W.G. Phylogeny of the bacterial superfamily of Crp-Fnr transcription regulators: exploiting the metabolic spectrum by controlling alternative gene programs. FEMS Microbiol. Rev., 2003, 27(5),559-92.
154. Akif, M.; Akhter, Y.; Hasnain, S.E.; Mande, S.C. Crystallization and preliminary X-ray crystallographic studies of Mycobacterium tuberculosis CRP/FNR family transcription regulator. Acta Cryst., 2006. F62, 873-875.
155. Tekaia, F.; Gordon, S.V.; Garnier, T.; Brosch, R.; Barrell, B.G.; Cole, S.T. Analysis of the proteome of Mycobacterium tuberculosis in silico. Tuber Lung Di., 1999, 79, 329-342
156. Chopra, P.; Meena, L.S.; Singh, Y. New drug targets for Mycobacterium tuberculosis. Indian J Med Res., 2003, 117, 1-9.
157. [Collins, D.M.; Kawakami, R.P.; de Lisle, G.W.; Pascopella, L.; Bloom, B.R.; Jacobs, W.R. Jr. Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA., 1995, 92, 8036-40
158. Gomez, M.; Doukhan, L.; Nair, G.; Smith, I. sigA is an essential gene in Mycobacterium smegmatis. Mol Microbiol., 1998, 29, 617-628.
159. Manganelli, R.; Provvedi, R.; Rodrigue, S.; Beaucher, J.; Gaudreau, L.; Smith, I. Sigma factors and global gene regulation in Mycobacterium tuberculosis. Bacteriol, 2004, 186, 895-902.
160. Dainese, E.; Rodrigue, S.; Delogu, G. et al. Posttranslational regulation of Mycobacterium tuberculosis extracytoplasmicfunction sigma factor SigL and roles in virulence and in global regulation of gene expression. Infect. Immun., 2006, 74: 2457-2461.
161. Mukherjee, R.; Gomez, M.; Jayaraman, N.; Smith, I.; Chatterji, D. Hyperglycosylation of glycopeptidolipid of Mycobacterium smegmatis under nutrient starvation: structural studies. Microbiology, 2005, 151: 2385-2392.
162. Doukhan, L.; Predich, M.; Nair, G.; Dussurget, O.; Mandic-Mulec, I.; Cole, S.T. et al. Genomic organization of the mycobacterial sigma gene cluster. Gene, 1995, 165, 67-70.
163. [Wu, Q.L.; Kong, D.; Lam, K.; Husson, R.N. A mycobacterial extracytoplasmic function sigma factor involved in survival following stress. J Bacteriol., 1997, 179, 2922-9.
164. Manganelli, R.; Dubnau, E.; Tyagi, S.; Kramer, F.R.; Smith, I. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mo. Microbiol., 1999, 1, 715-724.
165. Chen, P.; Ruiz, R.E.; Li, Q.; Silver, R.F.; Bishai, W.R. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect. Immun., 2000, 68, 5575-80.
166. DeMaio, J., Zhang, Y., Ko, C., Young, D. B. & Bishai, W. R. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA., 1996, 93, 2790-2794.
167. Rodrigue, S.; Provvedi, R.; Jacques, P.; Gaudreau, L.; Manganelli, R. The sigma factors of Mycobacteriumtuberculosis. FEMS Microbio. Rev., 2006, 30, 926-941
168. Raman, S.; Song, T.; Puyang, X.; Bardarov, S.; Jacobs, W.R. Jr, Husson RN. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J. Bacteriol., 2001, 183, 6119-6125.
169. R.; Voskuil, M.I.; Schoolnik, G.K.; Dubnau, E.; Gomez, M.; Smith, I. Role of the extracytoplasmic- function sigma factor sigma(H) in Mycobacterium tuberculosis global gene expression. Mol Microbiol., 2002 45,365-374.
170. Gasior, S.L.; Olivares, H.; Ear, U., Hari, D.M.; Weichselbaum, R.; Bishop, D.K. Assembly of RecA-like recombinases: Distinct roles from mediator proteins in mitosis and meiosis. Proc. Natl. Acad. Sci. 2001, 98,8411-8418.
171. Kowalczykowski, S.C.; Krupp, R.A. DNA-strand exchange promoted by RecA protein in the absence of ATP: Implications for the mechanism of energy transduction in protein-promoted nucleic acid transactions. Proc. Natl. Acad. Sci,. 1995, 92, 3478-3482.
172. Sander, P.; Böttger, E.C.; Springer, B.; Steinmann, B.; Rezwan, M.; Stavropoulos, E.; Colston, M.J. A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability. Vaccine. 2003, 21, 4124-4127.
173. Keller, P.M.; Böttger, E.C.; Sander, P. Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant. BMC Microbiol. 2008, 8,120.
174. Wigle, T.J.; Singleton, S.F. Directed molecular screening for RecA ATPase inhibitors. Bioorg Med Chem Lett. 2007, 17, 3249-3253.
175. Pestryakov, P.E.; Lavrik, O. I. Mechanisms of Single-Stranded DNA-Binding Protein Functioning in Cellular DNA Metabolism. Biochemistry, 2008, 73, 1388-1404.
176. Shamoo, Y.; Friedman, A.M.; Parsons, M.R.; Konigsberg, W.H.; Steitz, T.A. Crystal structure of a replication fork single stranded DNA binding protein (T4 gp32) complexed to DNA. Nature, 1995, 376, 362-366.
177. Stassen, A.P.; Folmer, R.H.; Hilbers, C.W.; Konings, R.N. Singlestranded DNA binding protein encoded by the filamentous bacteriophage M13: structural and functional characteristics. Mol. Biol. Rep., 1995, 20, 109-127.
178. Bochkarev, A.; Pfuetzner, R.A.; Edwards, A.M.; Frappier, L. Structure of the single-stranded-DNA- binding domain of replication protein A bound to DNA. Nature, 1997, 385,176-181.
179. Raghunathan, S.; Ricard, C.S.; Lohman, T.M.; Waksman, G. Crystal structure of the homo-tetrameric DNA binding domain of Escherichia coli single-stranded DNA-binding protein determined by multiwavelength X-ray diffraction on the selenomethionyl protein at 2.0 Å resolution. Proc. Natl Acad. Sci. USA., 1997, 94, 6652-6657.
180. Yang, C.; Curth, U.; Urbanke, C.; Kang, C. Crystal structure of human mitochondrial single-stranded DNA binding protein at 2.4 Å resolution. Nat. Struct Biol., 1997, 4,153-157.
181. Vijayan, M. Structural genomics of microbial pathogens -An Indian programme. Current Science, 2003, 85:878-885.
182. Purnapatre, K.; Varshney, U. Cloning, over-expression and biochemical characterization of the single-stranded DNA binding protein from Mycobacterium tuberculosis. Eur. J. Biochem., 1999, 264, 591-598.
183. Handa, P.; Acharya, N.; Thanedar, S.; Purnapatre, K.; Varshney, U. Distinct properties of Mycobacterium tuberculosis single-stranded DNA binding protein and its functional characterization in Escherichia coli. Nucleic Acids Res., 2000,28(19),3823-9.
184. Perham, R.N. Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. Annu. Rev. Biochem., 2000, 69, 961-1004.
185. Ma, Q.; Zhao, X.; Nasser Eddine, A.; Geerlof, A.; Li, X.; Cronan, J.E.; Kaufmann, S.H.; Wilmanns, M. The Mycobacterium tuberculosis LipB enzyme functions as a cysteine/lysine dyad acyltransferase. Proceedings of the National Academy of Sciences US, 2006, 103, 8662-8667.
186. Rachmann, H.; Strong, M.; Ulrichs, T.; Grode, L.; Schuchhardt, J.; Mollenkopf, H.; Kosmiadi, G. A.; Eisenberg, D.; Kaufmann, S. H. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect. Immun., 2006, 74, 1233-1242.
187. Das, S.; Kumar, P.; Bhor, V.; Surolia, A.; Vijayan, M. Invariance and variability in bacterial PanK: a study based on the crystal structure of Mycobacterium tuberculosis PanK. Acta Crystallographica, 2006, 62(6), 628-638.
188. Cole, S.T.; Eiglmeier, K.; Parkhill, J.; James, K.D.; Thomson, N.R.; Wheeler, P.R.; Honore, N.; Garnier, T.; Churcher, C.; Harris, D. et al. Massive gene decay in the leprosy bacillus. Nature, 2001, 409,1007-1011
189. Sambandamurthy, V.K.; Wang, X.; Chen, B.; Russell, R.G.; Derrick, S.; Collins, F.M., Morris, S.L.; Jacobs, W.R. Jr, A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med., 2002, 8, 1171-1174.
190. Visca, P.; Fabozzi, G.; Milani, M.; Bolognesi, M.; Ascenzi, P. Nitric oxide and Mycobacterium leprae pathogenicity. IUBMB Life, 2002, 54, 95-99.
191. Chaudhuri, B.N.; Sawaya, M.R.; Kim, C.Y.; Waldo, G.S. Park, M.S., Terwilliger, T.C., and Yeates, T.O. The crystal structure ofthe first enzyme in the pantothenate biosynthetic pathway, ketopantoate hydroxymethyltransferase, from M tuberculosis. Structure, 2003, 11, 753-764.
192. Wang, S.; Eisenberg, D. Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexeswith substrates and a reaction intermediate. Protein Sci., 2003, 1, 2, 1097-1108.
193. Chetnani, B.; Das, S.; Kumar, P.; Surolia, A.; Vijayan, M. Mycobacterium tuberculosis pantothenate kinase: possible changes in location of ligands during enzyme action. Acta Crystallogr D Biol Crystallography., 2009, 65, 312-325.
194. Berthet, F.X.; Lagranderie, M.; Gounon, P.; Laurent-Winter, C.; Ensergueix, D.; Chavarot, P. et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science, 1998, 282, 759-62.
195. Cox, J.S.; Chen, B.; McNeil, M.; Jacobs, W.R. Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature, 1999, 402, 79-83.
196. Alksne, L.E.; Projan, S.J. Bacterial virulence as a target for antimicrobial chemotherapy. Curr. Opin. Biotechnol., 2000, 11, 625-36.
197. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry III C.E. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
198. Leonard, C.J.; Aravind, L.; Koonin, E.V. Novel families of putative protein kinases in bacteria and archaea: Evolution of the 'eukaryotic' protein kinase superfamily. Genome Res., 1998,8, 1038-1047.
199. Av-Gay, Y.; Everett. M. The eukaryotic-like serine threonine kinase of Mycobacterium tuberculosis. Review. Trends in Microbiology, 2000, 8,238-244.
200. Vohra, R.; Gupta, M.; Chaturvedi, R.; Singh, Y. Attack on the scourge of Tuberculosis: Patented Drug Targets. Recent Pat. Antiinfect. Drug Discov., 2006, 1, 95-106.
201. Wehenkel, A.; Bellinzoni, M.; Grana, M.; Duran, R.; Villarino, A.; Fernandez, P.; Andre-Leroux G.; et al. Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. Biochim Biophys Acta, 2008, 1784, 193-202.
202. Szekely, R.; Waczek, F.; Szabadkai, I.; Németh, G.; Hegymegi-Barakonyi, B.; Eros, D.; Szokol, B.; Pató, J.; Hafenbradl, D. et al. A novel drug discovery concept for tuberculosis:inhibition of bacterial and host cell signalling. Immunol, Lett., 2008, 116, 225-231.
203. Drews, S. J.; Hung, F.; Av-Gay, Y. A protein kinase inhibitor as an antimycobacterial agent. FEMS Microbiol. Lett. 2001, 205,369-374.
204. Young, T. A.; Delagoutte, B.; Endrizzi, J. A.; Falick, A. M.; Alber, T. Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nature Struct. Biol., 2003, 10,168-174.
205. Pullen, K.E.; Ng, H.L.; Sung, P.Y.; Good, M.C.; Smith, S.M.; Alber, T. An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-Family Ser/Thr protein phosphatase. Structure, 2004, 12, 1947-1954.
206. Bach, H.; Wong, D.; Av-Gay, Y. Mycobacterium tuberculosis PtkA is a novel protein tyrosine kinase whose substrate is PtpA. Biochem J., 2009,420, 155-160.
207. Singh, R.; Rao, V.; Shakila, H.; Gupta, R.; Khera, A.; Dhar, N.; Singh, A.; et al. AK. Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol. Microbiol., 2003, 50, 751-762.
208. Grundner, C.; Perrin, D.; Hooft van Huijsduijnen, R.; Swinnen, D.; Gonzalez, J.; Gee, C.L.; Wells, T.N.; Alber, T. Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB. Structure,2007, 15, 499-509.
209. Zahrt, T.C.; Deretic, V. An essential two-component signal transduction system in Mycobacterium tuberculosis. J. Bacteriol., 2000, 182, 3832-8.
210. Dasgupta, N.; Kapur, V.; Singh, K.K.; Das, T.K.; Sachdeva, S.; Jyothisri, K.; et al. Characterization of a two-component system devR-devS, of Mycobacterium tuberculosis. Tuber. Lung Dis., 2000, 80, 141-59.
211. Perez, E.; Samper, S.; Bordas, Y.; Guilhot, C.; Gicquel, B.; Martin, C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol.Microbiol., 2001, 41, 179-87.
212. Dick,T. Dormant tubercle bacilli: the key to more effective TB chemotherapy?Antimicrob. Chemother., 2001, 47(1), 117-118.
213. Wayne, L.G. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis., 1994, 13(11), 908-14.
214. Zhang, Y. The magic bullets and tuberculosis drug targets. Annual Review of Pharmacology and Toxicology, 2005, 45, 529-564.
215. Segal, W., Bloch, H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol., 1956, 72, 132-141
216. Wheeler, P.R., and Ratledge, C. Use of carbon sources for lipid biosynthesis in Mycobacterium leprae: a comparison with other pathogenic mycobacteria. J. Gen. Microbiol., 1988, 134, 2111-2121.
217. McKinney, J.D., Jacobs, W.R.J. and Bloom, B.R. (1998) In "Emerging Infections". Krause, R.M. (ed.). 51-146. Academic Press, New York. Krause, R.M. (ed.). 51-146. Academic Press, New York.
218. McKinney, J.D.; Honer zu Bentrup, K.; Munoz-Elias, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R.; Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-738.
219. Segal, W. (1994) In "The Mycobacteria - A Source Book". Kubica, G.P. and Wayne, L.G. (eds),. 547-573. Marcel Dekkar Inc., New York.
220. Rohde,K.; Yates, R.M., Purdy,G.E., Russell, D.G. Mycobacterium and environment within the phagosome. Immunol Rev., 2007, 219, 37-54.
221. Bhowruth, V., Dover, L.G.; Besra, G.S. Tuberculosis Chemotherapy, Recent Developments and Future Perspectives. Progress in Medicinal Chemistry, 2007, 45, 169-203.
222. Dunn, M. F.; Ramirez-Trujillo, J. A.; Hernandez-Lucas, I. Major roles of isocitrate lyase and malate synthase in bacterial and fungal pathogenesis. Microbiology, 2009, 155, 3166-3175.
223. Höner Zu Bentrup, K., A. Miczak, D. L. Swenson, and D. G. Russell. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol., 1999, 181, 7161-7167.
224. Muñoz-Elías, E.J.; McKinney, J.D. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nature Medicine, 2005, 11, 638-644.
225. Gengenbacher, M.; Rao, S.P.; Pethe, K.; Dick, T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology, 2010, 156, 81-87.
226. Höner B. K.; Russell, D.G. Mycobacterial persistence: adaptation to a changing environment. Trends in Microbiology, 2001. 9(12), 597-605.
227. Muñoz-Elías, E. J.; Upton, A. M.; Cherian, J.; McKinney, J. D. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol. Microbiol., 2006, 60, 1109-1122.
228. Russell, D.G.; Brian, C.; Wonsik, L.V.; Abramovitch, R.B.; Kim, M., Homolka, S.; Niemann, S. Rohde, K.H. Mycobacterium tuberculosis wears What It Eats. Cell Host & Microbe, 2010, 8, 1, 68-76, 22.
229. Sharma, V.; Sharma, S.; Hoener zu Bentrup, K.; McKinney, J.D.; Russell, D.G.; Jacobs, W.R. Jr.; Sacchettini, J.C. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Na.t Struct. Biol, 2000, 7(8), 663-8.
230. Butler, S.M.; Festa, R.F.; Pearce, M.J.; Darwin, K.H. Selfcompartmentalized Bacteria Proteases and Pathogenesis. Mol. Microbiol, 2006, 60,553-562.
231. Baumeister, W.; Walz, J.; Zuhl, F.; Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell, 1998, 92, 367-380.
232. Voges, D.; Zwickl, P.; Baumeister, W. The 26S proteasome:a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem, 1999, 68, 1015-1068.
233. Goldberg, A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans., 2007, 35, 12-17.
234. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev.Biochem., 1998, 67, 425-479.
235. Darwin, K.H.; Ehrt, S.; Gutierrez-Ramos, J.C.; Weich, N.; Nathan, C.F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science, 2003,302, 1963-1966.
236. Gandotra, S.; Schnappinger, D.; Monteleone, M.; Hillen, W.; Ehrt, S. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med., 2007, 13, 1515-1520.
237. Lin, G.; Li, D.; de Carvalho, L.P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J.D. et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461, 621-626.
238. Tripathi, R.P.; Tewari, N.; Dwivedi, N.; Tiwari, V.K. Fighting tuberculosis: An old disease with new challenges. Medicinal Research Reviews, 2005, 25(1), 93-131.